Drug-Drug Interactions with Direct Oral Anticoagulants
Open Access
- 1 August 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Clinical Pharmacokinetics
- Vol. 59 (8), 967-980
- https://doi.org/10.1007/s40262-020-00879-x
Abstract
A large body of evidence suggests that not only direct anticoagulant effects but also major bleeding events and stroke prevention depend on plasma concentrations of direct oral anticoagulants (DOACs). Concomitant drugs that cause drug-drug interactions (DDIs) alter DOAC exposure by increasing or decreasing DOAC bioavailability and/or clearance; hence, they might affect the efficacy and safety of DOAC therapy. Patients with renal impairment already receive smaller DOAC maintenance doses because avoidance of elevated DOAC exposure might prevent serious bleeding events. For other causes of increased exposure such as DDIs, management is often less well-defined. Considering that DOAC patients are often older and have multiple co-morbidities, polypharmacy is highly prevalent. However, the effect of multiple drugs on DOAC exposure, and especially the impact of DDIs when concurring with drug-disease interactions as observed in renal impairment, has not been thoroughly elucidated. In order to provide effective and safe anticoagulation with DOACs, understanding the mechanisms and magnitude of DDIs appears relevant. Instead of avoiding drug combinations with DOACs, more DDI trials should be conducted and new strategies such as dose adjustments based on therapeutic drug monitoring should be investigated. However, dose adjustments based on concentration measurements cannot currently be recommended because evidence-based data are missing.Funding Information
- Horizon 2020 (754517)
This publication has 110 references indexed in Scilit:
- Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa InhibitorAmerican Journal of Cardiovascular Drugs, 2013
- Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitorClinical Pharmacology: Advances and Applications, 2013
- New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysisEuropean Heart Journal, 2013
- Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjectsBritish Journal of Clinical Pharmacology, 2013
- Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteersEuropean Journal of Clinical Pharmacology, 2012
- Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I StudyPharmaceuticals, 2012
- Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitorBritish Journal of Clinical Pharmacology, 2010
- Impact of Proteinuria and Glomerular Filtration Rate on Risk of Thromboembolism in Atrial FibrillationCirculation, 2009
- The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjectsBritish Journal of Clinical Pharmacology, 2007
- Rivaroxaban (BAY 59‐7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxenBritish Journal of Clinical Pharmacology, 2006